Lisocabtagene Maraleucel Has High Efficacy in R/R MZL

03 Mar 20264 min read0 viewsJournal Feed

GIST

Nature Reviews Clinical Oncology published a clinical update in Oncology on 03 Mar 2026. The item focuses on Lisocabtagene maraleucel has high efficacy in R/R MZL. Review the original article for the full source wording and details.

Clinical Editorial

Summary

Nature Reviews Clinical Oncology published a clinical update in Oncology on 03 Mar 2026.

The item focuses on Lisocabtagene maraleucel has high efficacy in R/R MZL.

Review the original article for the full source wording and details.

Source Reference

Read the full original publication from the source journal or publisher link below.

Open Original Source More Feed Items

Related by Condition/Drug

ClinicalTrialsRelated by Conditionlymphoma

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Oncology • 13 Mar 2026

ClinicalTrialsRelated by Conditionlymphoma

Nemtabrutinib Plus Venetoclax vs Venetoclax Plus Rituximab in Relapsed/Refractory CLL/SLL

Oncology • 13 Mar 2026

PLOS ONERelated by Conditionlymphoma

Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study

Research Highlights • 22 May 2026

BloodRelated by Conditionlymphoma

Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis - ashpublications.org

Oncology • 23 Apr 2026

BloodRelated by Conditionlymphoma

Expression of cFLIP in B cells is essential for diffuse large B-cell lymphoma pathogenesis - ashpublications.org

Oncology • 23 Apr 2026

Nat Rev OncRelated by Conditionlymphoma

Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders

Oncology • 15 Apr 2026

Feed Metadata

Source

Nature Reviews Clinical Oncology